Study wrapper · #1351
Recent Advances in Glucagon-Like Peptide-1 Receptor and Melanocortin-4 Receptor Agonists for the Treatment of Obesity and Type 2 Diabetes.
Lee CM, Kim JY, Shim JH, et al. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2026.
DOI: 10.1055/a-2928-5204PubMed: 42697206
Editor's note
A broad literature review that favors breadth over depth, pairing the mainstream incretin class with the smaller melanocortin-4 field best known for setmelanotide in genetic obesity. It offers no systematic search methodology or pooled analysis, so it is best read as a mechanism-and-landscape primer. The efficacy characterizations are consistent with the published trial record.
Plain-language abstract
This review surveys two drug families for obesity and type 2 diabetes — GLP-1 receptor agonists such as semaglutide and melanocortin-4 receptor agonists such as setmelanotide — and covers newer dual and triple agonists like tirzepatide plus oral formulations designed to improve adherence.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Mixed
Sleeve gastrectomy versus tirzepatide to improve survival among patients with stage 5 CKD: A Markov decision analysis.
American journal of surgeryn=——2026
Mixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. An=——2026